Literature DB >> 1082343

Factors influencing prognosis in adults with acute myelogenous leukaemia.

D Crowther, M E Beard, C J Bateman, R L Sewell.   

Abstract

A study of the thymidine labelling index (TLI) of bone marrow blast cells in 58 untreated patients with acute myelogenous leukemia showed no correlation with remission rate but there was a strong correlation between labelling index and remission length in the 21 patients who achieved remission. The median remission length of the patients was 33 weeks. Of the 12 patients with initial labelling indices greater than 10%, only 2 had remissions longer than 33 weeks whereas 8 of the 9 patients with labelling indices less than 10% had remissions longer than 33 weeks. No correlation could be found between the degree of cytological differentiation and remission induction, remission length or survival. No correlation was found between the TLI and the degree of cytological differentiation. Age and initial platelet count were confirmed to be important factors influencing complete remission rate, but these factors did not correlate with remission length. Sixteen patients had their pretreatment sera assayed for mouse marrow colony stimulating activity and inhibitor levels but there was no correlation with subsequent response to treatment, although the number of patients examined was clearly too small for any definite conclusions to be drawn.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1082343      PMCID: PMC2024759          DOI: 10.1038/bjc.1975.247

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Correlation of cytosine arabinoside-induced increment in growth fraction of leukemic blast cells with clinical response.

Authors:  W R Vogler; L E Cooper; D P Groth
Journal:  Cancer       Date:  1974-03       Impact factor: 6.860

2.  The growth of mouse bone marrow cells in vitro.

Authors:  T R Bradley; D Metcalf
Journal:  Aust J Exp Biol Med Sci       Date:  1966-06

3.  Factors influencing microculture in leukaemia cells.

Authors:  F Balkwill; A Pindar; D Crowther
Journal:  Nature       Date:  1974-10-25       Impact factor: 49.962

4.  Clinical classification and evaluation of treatment response in acute myeloid leukaemia on the basis of differences of leukaemic cell differentiation.

Authors:  H Brincker
Journal:  Scand J Haematol       Date:  1973

5.  Acute myelocytic leukemia in adults.

Authors:  B D Clarkson
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

6.  Management of adult acute myelogenous leukaemia.

Authors:  D Crowther; R L Powles; C J Bateman; M E Beard; C L Gauci; P F Wrigley; J S Malpas; G H Fairley; R B Scott
Journal:  Br Med J       Date:  1973-01-20

7.  Acute promyelocytic leukemia: results of treatment by daunorubicin.

Authors:  J Bernard; M Weil; M Boiron; C Jacquillat; G Flandrin; M F Gemon
Journal:  Blood       Date:  1973-04       Impact factor: 22.113

8.  Leukopoietic activity in human urine. The granulocytic leukemias.

Authors:  W A Robinson; B L Pike
Journal:  N Engl J Med       Date:  1970-06-04       Impact factor: 91.245

9.  Responsiveness of human granulocytic leukemic cells to colony-stimulating factor.

Authors:  D Metcalf; M A Moore; J W Sheridan; G Spitzer
Journal:  Blood       Date:  1974-06       Impact factor: 22.113

10.  Physical separation of colony stimulating cells from in vitro colony forming cells in hemopoietic tissue.

Authors:  M A Moore; N Williams
Journal:  J Cell Physiol       Date:  1972-10       Impact factor: 6.384

View more
  10 in total

1.  Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications.

Authors:  H M Kantarjian; B Barlogie; M J Keating; R R Hall; T L Smith; K B McCredie; E J Freireich
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

2.  Routine bone marrow examination in the management of acute lymphoblastic leukaemia of childhood.

Authors:  C Haworth; A D Heppleston; P H Morris Jones; R H Campbell; D I Evans; M K Palmer
Journal:  J Clin Pathol       Date:  1981-05       Impact factor: 3.411

3.  Proliferation patterns in acute myeloid leukemia: leukemic clonogenic growth and in vivo cell cycle kinetics.

Authors:  P P Brons; C Haanen; J B Boezeman; P Muus; R S Holdrinet; A H Pennings; H M Wessels; T de Witte
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

4.  Autologous leukemia-specific T-cell-mediated lymphocytotoxicity in patients with acute myelogenous leukemia.

Authors:  S K Lee; R T Oliver
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

5.  Serum thymidine kinase in acute leukaemia.

Authors:  H Hagberg; S Gronowitz; A Killander; C Källander; B Simonsson; C Sundström; G Oberg
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

6.  Effects of cell density on drug-induced cell kill kinetics in vitro (inoculum effect).

Authors:  T Ohnuma; H Arkin; J F Holland
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

7.  Assessment of drug sensitivity of human leukaemic myeloblasts. I. Labelling human myeloblasts with 125IUdR for survival studies in mice.

Authors:  R P Falcão; S Sonis; I C MacLennan; D Chassoux; A J Davies; T R Munro
Journal:  Br J Cancer       Date:  1977-09       Impact factor: 7.640

8.  Assessment of drug sensitivity of human leukaemic myeloblasts. II. The toxic effects of cytosine arabinoside on 125IUdR-labelled human leukaemic myeloblasts in mice.

Authors:  S T Sonis; R Falcão; I C MacLennan
Journal:  Br J Cancer       Date:  1977-09       Impact factor: 7.640

9.  Relationship between the pretreatment proliferative activity of marrow blast cells and prognosis of acute lymphoblastic leukaemia of childhood.

Authors:  J H Scarffe; I M Hann; D I Evans; P Morris Jones; M K Palmer; J S Lilleyman; D Crowther
Journal:  Br J Cancer       Date:  1980-05       Impact factor: 7.640

10.  Lack of prognostic value of the thymidine-labelling index in adult acute leukaemia.

Authors:  R L Sewell; T A Lister; S A Johnson; D Crowther
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.